As MDMG-935P potently lowered hepatic oxalate, steatosis, inflammation and fibrosis in mice with established MASH, further evaluation of GO and LDHA inhibition for concurrent treatment of MASH and associated cardiovascular disease is warranted. The gene discussed is LDHA; the disease is steatosis.